Respiratory Syncytial Virus (RSV) Therapeutics Market to hit USD 4.64 Bn by 2032 at CAGR of 14.5%

The Respiratory Syncytial Virus (RSV) Therapeutics Market is growing rapidly owing to rising RSV awareness, which is a comprehensive health threat, and the creation of treatment alternative modes. Respiratory syncytial virus (RSV), is a common cause of respiratory disease, especially in infants and young children, as well as in older adults. In the US, RSV causes around 58,000–80,000 hospitalizations in children under 5 years of age and 60,000–160,000 hospitalizations in adults aged 65 years and older each year, according to the US Centers for Disease Control and Prevention (CDC). RSV\'s burden has encouraged governments around the world to prioritize its prevention and treatment. In September 2024, the British government rolled out the first-ever national RSV vaccination program in the world, protecting both infants and pregnant women/stage shift. This campaign is intended to lessen any winter pressure on the National Health Service (NHS) and reflects the increasing awareness of RSV as an important public health issue.